IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
79 hedge funds and large institutions have $208M invested in IGM Biosciences in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 16 reducing their positions, and 15 closing their positions.
131% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 16
36% more call options, than puts
Call options by funds: $226K | Put options by funds: $166K
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
10.29% more ownership
Funds ownership: 61.26% → 71.55% (+10%)
7% more funds holding
Funds holding: 74 → 79 (+5)
15% less capital invested
Capital invested by funds: $245M → $208M (-$37.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.4M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.5M |
| 4 |
Millennium Management
New York
|
+$10.4M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$9.78M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$4.06M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$3.03M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.78M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.67M |
IGMS Hedge Fund Activity: Q2 2023 in Review
79 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q2 2023, worth a combined $208M — down 15% from $245M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new IGMS positions and 15 closed out — a net gain of 5 holders — while 37 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $14.4M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $9.78M sold.
- 79 institutional investors held IGM Biosciences (IGMS) as of Q2 2023, up from 74 in Q1 2023.
- Funds reported $208M of IGM Biosciences stock for Q2 2023, down 15% quarter-over-quarter.
- 20 funds opened new IGM Biosciences positions in Q2 2023 and 15 closed out, a net change of +5 holders.
- The largest IGM Biosciences buyer in Q2 2023 was Fidelity Investments, an estimated $14.4M added.
- The largest IGM Biosciences seller in Q2 2023 was Alkeon Capital Management, an estimated $9.78M sold.
Based on aggregated 13F filings for Q2 2023.